Cover Image
市場調查報告書

類固醇17-α-羥化酶/17,20裂合酶:開發中產品分析

Steroid 17-Alpha-Hydroxylase/17,20 Lyase - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 365793
出版日期 內容資訊 英文 72 Pages
訂單完成後即時交付
價格
Back to Top
類固醇17-α-羥化酶/17,20裂合酶:開發中產品分析 Steroid 17-Alpha-Hydroxylase/17,20 Lyase - Pipeline Review, H1 2016
出版日期: 2016年06月30日 內容資訊: 英文 72 Pages
簡介

本報告提供以類固醇17-α-羥化酶/17,20裂合酶為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,加上企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

類固醇17-α-羥化酶/17,20裂合酶概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Asana BioSciences, LLC
  • Endo Pharmaceuticals Inc.
  • Johnson & Johnson
  • Leon-Nanodrugs GmbH
  • Millennium Pharmaceuticals, Inc.
  • Novartis AG
  • Orion Oyj
  • Tokai Pharmaceuticals, Inc.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0268TDB

Summary

Global Markets Direct's, 'Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) - Pipeline Review, H1 2016', provides in depth analysis on Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) targeted pipeline therapeutics.

The report provides comprehensive information on the Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30)
  • The report reviews Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) Overview
  • Therapeutics Development
    • Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) - Products under Development by Stage of Development
    • Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) - Products under Development by Therapy Area
    • Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) - Products under Development by Indication
  • Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) - Products under Development by Companies
  • Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) - Products under Development by Universities/Institutes
  • Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) - Companies Involved in Therapeutics Development
    • Asana BioSciences, LLC
    • Endo Pharmaceuticals Inc.
    • Johnson & Johnson
    • Leon-Nanodrugs GmbH
    • Millennium Pharmaceuticals, Inc.
    • Novartis AG
    • Orion Oyj
    • Tokai Pharmaceuticals, Inc.
  • Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) - Drug Profiles
    • abiraterone acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • abiraterone acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASN-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CFG-920 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EN-3356 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • galeterone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ketoconazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ODM-204 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • orteronel - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • seviteronel - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit CYP17 and CYP11B2 for Prostate Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit CYP17 Lyase - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) - Dormant Projects
  • Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) - Discontinued Products
  • Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) - Featured News & Press Releases
    • May 18, 2016: Janssen to Present Data on Abiraterone acetate at the 2016 American Society of Clinical Oncology Annual Meeting
    • May 18, 2016: Tokai Announces Publication of Three Abstracts on Galeterone at the 2016 ASCO Annual Meeting
    • May 12, 2016: Innocrin Pharmaceuticals Begins Phase 2 Study of Seviteronel in Women with Estrogen Receptor-positive or Triple-negative Breast Cancer and Expands Two Phase 2 Studies of Seviteronel in Men with Metastatic Castrate-resistant Prostate Cancer
    • Apr 26, 2016: Tokai Announces Oral Presentation on Galeterone at the 2016 AUA Annual Meeting
    • Mar 30, 2016: Tokai Announces Dosing of First Patient in Phase 2 Expansion Study of Galeterone in Enzalutamide-Refractory mCRPC Patients
    • Mar 21, 2016: NICE recommends abiraterone for prostate cancer
    • Mar 14, 2016: Greater Survival Benefit Shown in Men with Early and Less Aggressive Metastatic Castration-Resistant Prostate Cancer Treated with ZYTIGA Plus Prednisone
    • Jan 08, 2016: Tokai Announces Presentation of New Data Highlighting Unique Galeterone Mechanism at ASCO Genitourinary Cancers Symposium
    • Jan 07, 2016: Tokai Announces Update on ARMOR3-SV and Expanded Galeterone Clinical Development Program
    • Jan 06, 2016: Innocrin Pharmaceuticals Granted Fast Track Designation by FDA for VT-464 Treatment of Patients with Metastatic Castrate-resistant Prostate Cancer
    • Dec 11, 2015: NICE publishes draft guidance on Abiraterone prostate cancer treatment
    • Dec 03, 2015: Study shows abiraterone acetate is useful even in most aggressive prostate cancers
    • Nov 07, 2015: Tokai Announces Presentation of Galeterone Data in Models of the AR-V7 Splice Variant at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
    • Nov 04, 2015: Blood test picks out prostate cancer drug resistance
    • Oct 08, 2015: Tokai Pharmaceuticals Announces Presentation of AR-V7 Clinical Trial Assay at the Prostate Cancer Foundation's Annual Scientific Retreat
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Asana BioSciences, LLC, H1 2016
  • Pipeline by Endo Pharmaceuticals Inc., H1 2016
  • Pipeline by Johnson & Johnson, H1 2016
  • Pipeline by Leon-Nanodrugs GmbH, H1 2016
  • Pipeline by Millennium Pharmaceuticals, Inc., H1 2016
  • Pipeline by Novartis AG, H1 2016
  • Pipeline by Orion Oyj, H1 2016
  • Pipeline by Tokai Pharmaceuticals, Inc., H1 2016
  • Dormant Projects, H1 2016
  • Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top